<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There is limited data on the role of <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> as a risk factor for cerebral veno-sinus <z:mp ids='MP_0005048'>thrombosis</z:mp> (CVT) in Indians </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the association between plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> (<z:chebi fb="0" ids="17230">Hcy</z:chebi>), <z:chebi fb="0" ids="25297">methylenetetrahydrofolate</z:chebi> reductase (MTHFR) C677T polymorphism, and CVT in 185 patients with aseptic CVT (puerperal 80 and nonpuerperal 105) and 248 healthy controls (puerperal 67 and nonpuerperal 181) </plain></SENT>
<SENT sid="2" pm="."><plain>Fasting <z:chebi fb="0" ids="17230">Hcy</z:chebi> was higher in patients compared to controls (20.25 ± 5.97 vs 9.81 ± 5.19 μmol/L, P &lt; .001) and associated with 4.54-fold (95% confidence interval [CI]: 2.74-7.53) increase in risk of CVT </plain></SENT>
<SENT sid="3" pm="."><plain>Risk was higher in puerperal (odds ratio [OR]: 8.7, 95% CI: 2.73-26.91) compared to nonpuerperal CVT (OR: 3.82, 95% CI: 2.09-6.96) </plain></SENT>
<SENT sid="4" pm="."><plain>Plasma <z:chebi fb="0" ids="17230">Hcy</z:chebi> was higher in MTHFR 677TT compared to 677CT and 677CC genotypes (34.44 ± 32.8 vs 25.81 ± 33.3 vs 18.50 ± 23.7 μmol/L, respectively, P &lt; .001), but the risk associated with MTHFR 677TT was insignificant (OR: 1.91, 95% CI: 0.53-7.06) </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> is a risk marker for Indian patients with aseptic CVT </plain></SENT>
<SENT sid="6" pm="."><plain>MTHFR 677TT genotype is not linked with CVT but is a determinant of plasma <z:chebi fb="0" ids="17230">Hcy</z:chebi> </plain></SENT>
</text></document>